 |
|
 |
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Division of Metabolic and Endocrine Diseases, Department of General Pediatrics, University Children’s Hospital, Heidelberg, Germany
Department of General Pediatrics, University Children’s Hospital, Düsseldorf, Germany
Objective. The aims of this study were to determine the impact of expanded newborn screening using tandem mass spectrometry (MS/MS) on the overall detection rate of inborn errors of metabolism in Germany and to assess the outcome for the patients that were diagnosed.
Methods. During the period of study, 250 000 neonates in a German population were investigated for 23 inborn errors of metabolism by electrospray ionization-MS/MS. The overall value of the screening program was estimated by 1) complete ascertainment of all positive tests; 2) definite assignment of all diagnoses including reconfirmation at 12 months; and 3) clinical follow-up of all detected patients in an overall interval of 42 months. The mean observation period was 13.5 months per child.
Results. In 106 newborns, confirmed inborn errors of metabolism were found. The disorders were classified as 50 classic forms and 56 variants. A total of 825 tests (0.33%) were false-positives. Seventy of the 106 newborns with confirmed disorders were judged to require treatment. Six children developed symptoms despite treatment. Three children had died. Among 9 children who became symptomatic before report of the results of screening, in 6 the diagnosis had been made in advance of the screening report. In evaluation of the screening program, 61 of the 106 identified children (58% of true-positives, or 1 of 4100 healthy newborns) were judged to have benefited from screening and treatment, because the diagnosis had not been made before screening. None of these infants had died and none developed psychomotor retardation or metabolic crisis during the follow-up period.
Conclusions. The screening by MS/MS for up to 23 additional disorders has approximately doubled the detection rate compared with that achieved by the conventional methods used in Germany. This strategy represents valuable preventive medicine by enabling diagnosis and treatment before the onset of symptoms.
Key Words: mass screening • metabolism • inborn errors • neonatal screening • outcome assessment • preventive medicine • spectrometry • mass • electrospray ionization
Abbreviations: FAO, fatty acid oxidation • CI, confidence interval • MCAD, medium-chain acyl-CoA dehydrogenase • MS/MS, tandem mass spectrometry • PKU, phenylketonuria
This article has been cited by other articles:
 |
|
 |
|
  A. Dajnoki, A. Muhl, G. Fekete, J. Keutzer, J. Orsini, V. DeJesus, X. K. Zhang, and O. A. Bodamer Newborn Screening for Pompe Disease by Measuring Acid {alpha}-Glucosidase Activity Using Tandem Mass Spectrometry Clin. Chem., October 1, 2008; 54(10): 1624 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Robbins and E. N. Leon-ruiz Anesthetic Management of a Patient with 3-Methylcrotonyl-CoA Carboxylase Deficiency Anesth. Analg., August 1, 2008; 107(2): 648 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-W. Hsu, T. H. Zytkovicz, A. M. Comeau, A. W. Strauss, D. Marsden, V. E. Shih, G. F. Grady, and R. B. Eaton Spectrum of Medium-Chain Acyl-CoA Dehydrogenase Deficiency Detected by Newborn Screening Pediatrics, May 1, 2008; 121(5): e1108 - e1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Kaler, C. S. Holmes, D. S. Goldstein, J. Tang, S. C. Godwin, A. Donsante, C. J. Liew, S. Sato, and N. Patronas Neonatal Diagnosis and Treatment of Menkes Disease N. Engl. J. Med., February 7, 2008; 358(6): 605 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bishop Hubbard Policy Issues Related to Expanded Newborn Screening: A Review of Three Genetic/Metabolic Disorders Policy Politics Nursing Practice, August 1, 2007; 8(3): 201 - 209. [Abstract] [PDF]
|
|
|
|
|
|
S. Ho, Z. Lukacs, G. F. Hoffmann, M. Lindner, and T. Wetter Feature Construction Can Improve Diagnostic Criteria for High-Dimensional Metabolic Data in Newborn Screening for Medium-Chain Acyl-CoA Dehydrogenase Deficiency Clin. Chem., July 1, 2007; 53(7): 1330 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. la Marca, S. Malvagia, E. Pasquini, M. Innocenti, M. A. Donati, and E. Zammarchi Rapid 2nd-Tier Test for Measurement of 3-OH-Propionic and Methylmalonic Acids on Dried Blood Spots: Reducing the False-Positive Rate for Propionylcarnitine during Expanded Newborn Screening by Liquid Chromatography-Tandem Mass Spectrometry Clin. Chem., July 1, 2007; 53(7): 1364 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Strnadova, M. Holub, A. Muhl, G. Heinze, R. Ratschmann, H. Mascher, S. Stockler-Ipsiroglu, F. Waldhauser, F. Votava, J. Lebl, et al. Long-Term Stability of Amino Acids and Acylcarnitines in Dried Blood Spots Clin. Chem., April 1, 2007; 53(4): 717 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Green, S. M. Dolan, and T. H. Murray Newborn Screening: Complexities in Universal Genetic Testing Am J Public Health, November 1, 2006; 96(11): 1955 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. T. van Maldegem, M. Duran, R. J. A. Wanders, K. E. Niezen-Koning, M. Hogeveen, L. Ijlst, H. R. Waterham, and F. A. Wijburg Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. JAMA, August 23, 2006; 296(8): 943 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Waisbren Newborn screening for metabolic disorders. JAMA, August 23, 2006; 296(8): 993 - 995. [Full Text] [PDF]
|
|
|
|
|
|
B. A. Tarini, D. A. Christakis, and H. G. Welch State Newborn Screening in the Tandem Mass Spectrometry Era: More Tests, More False-Positive Results Pediatrics, August 1, 2006; 118(2): 448 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Gurian, D. D. Kinnamon, J. J. Henry, and S. E. Waisbren Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics, June 1, 2006; 117(6): 1915 - 1921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Feuchtbaum and G. Cunningham Economic Evaluation of Tandem Mass Spectrometry Screening in California Pediatrics, May 1, 2006; 117(5/S1): S280 - S286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Acharya, P. D. Ackerman, and L. F. Ross Pediatricians' Attitudes Toward Expanding Newborn Screening Pediatrics, October 1, 2005; 116(4): e476 - e484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Amir, V. R. Sutton, and I. B. Van den Veyver Newborn Screening and Prenatal Diagnosis for Rett Syndrome: Implications for Therapy J Child Neurol, September 1, 2005; 20(9): 779 - 783. [Abstract] [PDF]
|
|
|
|
|
|
R. E. Amir, V. Reid Sutton, and I. B. Van den Veyver Newborn Screening and Prenatal Diagnosis for Rett Syndrome: Implications for Therapy J Child Neurol, August 1, 2005; 20(8): 779 - 783. [Abstract] [PDF]
|
|
|
|
|
|
C. T. Cavedon, P. Bourdoux, K. Mertens, H. V. Van Thi, N. Herremans, C. de Laet, and P. Goyens Age-Related Variations in Acylcarnitine and Free Carnitine Concentrations Measured by Tandem Mass Spectrometry Clin. Chem., April 1, 2005; 51(4): 745 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, C. R. Scott, N. A. Chamoles, A. Ghavami, B. M. Pinto, F. Turecek, and M. H. Gelb Direct Multiplex Assay of Lysosomal Enzymes in Dried Blood Spots for Newborn Screening Clin. Chem., October 1, 2004; 50(10): 1785 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wilcken Screening of Newborns for Metabolic Disorders With Mass Spectrometry JAMA, March 24, 2004; 291(12): 1444 - 1444. [Full Text] [PDF]
|
|
|
|
|
|
N. A. Holtzman Expanding Newborn Screening: How Good Is the Evidence? JAMA, November 19, 2003; 290(19): 2606 - 2608. [Full Text] [PDF]
|
|
 |
||
|
||
Home | My Pediatrics | Journal Information | Current Issue | Past Issues | Subscriptions & Services | Contact Us Click here for faster international access © 2003 American Academy of Pediatrics. All rights reserved. |
||
|
||
